CBIO

20.35

1.88% -0.39

Handel nachbörslich: 19.95 -0.40 -1.97%

Crescent Biopharma Inc (CBIO)

Überblick Nachrichten Preisverlauf Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$20.74

Offen:

$20.65

24-Stunden-Volumen:

326.28K

Relative Volume:

1.33

Marktkapitalisierung:

$561.15M

Einnahmen:

$11.88M

Nettoeinkommen (Verlust:

$-162.08M

KGV:

-1.6301

EPS:

-12.484

Netto-Cashflow:

$-156.43M

1W Leistung:

+10.12%

1M Leistung:

-17.94%

6M Leistung:

+34.95%

1J Leistung:

+3,880%

1-Tages-Spanne:

$19.70

$21.14

1-Wochen-Bereich:

$18.40

$21.24

52-Wochen-Spanne:

$8.72

$27.41

Crescent Biopharma Inc Stock (CBIO) Company Profile

Firmenname

Crescent Biopharma Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (621)

Telefon

617-430-5595

Adresse

300 FIFTH AVENUE, WALTHAM, CA

Mitarbeiter

Twitter

@catalystbio

Nächster Verdiensttermin

2026-05-13

Neueste SEC-Einreichungen

CBIO's Discussions on Twitter

Compare CBIO vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CBIO Crescent Biopharma Inc	20.35	571.90M	11.88M	-162.08M	-156.43M	-12.48
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Eingeleitet	Piper Sandler	Overweight
2026-01-21	Eingeleitet	Guggenheim	Buy
2025-08-25	Eingeleitet	Jefferies	Buy
2025-08-11	Eingeleitet	H.C. Wainwright	Buy
2025-07-14	Eingeleitet	Wedbush	Outperform
2025-06-25	Eingeleitet	Stifel	Buy
2025-03-21	Eingeleitet	Cantor Fitzgerald	Overweight
2025-03-11	Eingeleitet	Noble Capital Markets	Outperform
2024-07-26	Herabstufung	TD Cowen	Buy → Hold
2023-12-22	Eingeleitet	CapitalOne	Overweight
2021-11-12	Hochstufung	Jefferies	Hold → Buy
2021-04-29	Fortgesetzt	Stephens	Overweight
2021-02-10	Eingeleitet	Piper Sandler	Overweight
2020-05-21	Eingeleitet	Raymond James	Outperform
2019-11-14	Eingeleitet	ROTH Capital	Buy
2019-08-05	Herabstufung	Jefferies	Buy → Hold
2019-08-05	Herabstufung	Piper Jaffray	Overweight → Neutral
2019-08-05	Herabstufung	SunTrust	Buy → Hold
2019-04-12	Eingeleitet	Piper Jaffray	Overweight
2019-01-04	Eingeleitet	Oppenheimer	Outperform
2018-12-18	Eingeleitet	H.C. Wainwright	Buy
2018-02-12	Bestätigt	B. Riley FBR, Inc.	Buy
2018-02-09	Bestätigt	Chardan Capital Markets	Buy
2017-12-08	Eingeleitet	B. Riley FBR, Inc.	Buy
2017-06-12	Eingeleitet	Chardan Capital Markets	Buy
2017-06-06	Eingeleitet	Ladenburg Thalmann	Buy
2016-07-26	Eingeleitet	SunTrust	Buy
2016-06-30	Eingeleitet	Rodman & Renshaw	Buy
2015-03-17	Bestätigt	Stifel	Buy

Alle ansehen

Crescent Biopharma Inc Aktie (CBIO) Neueste Nachrichten

12:37 PM

CBIO: Four clinical studies launching in 2024 set up a data-rich 2027 for oncology pipeline decisions - TradingView

12:37 PM

May 22, 2026

Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

May 22, 2026

Crescent Biopharma to present CR-001 trial data at ASCO meeting - Investing.com Nigeria

May 22, 2026

May 21, 2026

Crescent Biopharma to present CR-001 trial data at ASCO meeting By Investing.com - Investing.com South Africa

May 21, 2026

Crescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027 - Quiver Quantitative

May 21, 2026

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 ... - Caledonian Record

May 21, 2026

Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027 - Stock Titan

May 21, 2026

May 15, 2026

Tang Capital entities disclose 1,160,000-share stake in Crescent Biopharma (CBIO) - Stock Titan

May 15, 2026

New Forecasts: Here's What Analysts Think The Future Holds For Crescent Biopharma, Inc. (NASDAQ:CBIO) - 富途牛牛

May 15, 2026

Balyasny entities disclose 1.51M shares in Crescent Biopharma (CBIO) - Stock Titan

May 15, 2026

May 12, 2026

CBIO Crescent Bio jumps 4% as Q1 loss beats estimates by 27%, pipeline progress lifts investor confidence.Trading Community - Newser

May 08, 2026

May 07, 2026

Rainbows and Unicorns: Crescent Biopharma, Inc. (NASDAQ:CBIO) Analysts Just Became A Lot More Optimistic - simplywall.st

May 07, 2026

May 06, 2026

Crescent Biopharma lines up 3 May conference webcasts for investors - Stock Titan

May 06, 2026

Crescent Biopharma to Present at May Investor Conferences - ChartMill

May 06, 2026

May 05, 2026

Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Sahm

May 05, 2026

May 04, 2026

H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22 - Moomoo

May 04, 2026

Crescent Biopharma (NASDAQ:CBIO) Trading Up 8.3%Here's Why - MarketBeat

May 04, 2026

May 03, 2026

The numbers behind Crescent Bio (CBIO) stock nobody talks about (Technical Weakness) 2026-05-03 - newser.com

May 03, 2026

MSN Money - MSN

May 03, 2026

May 01, 2026

Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $30 - Moomoo

May 01, 2026

Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga

May 01, 2026

Crescent Biopharma Down Over 16%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk - Moomoo

May 01, 2026